Tania Thomas is an Infectious Disease physician affiliated with University of Virginia. OpenAlex indexes 82 publications with 1,213 citations (h-index 18); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- Tuberculosis in Rural and Malnourished Populations
Sponsor: University of Virginia
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
60.8%Macrolide Antimicrobial60.8%Azithromycin100%Part D≥45 patientsAntiparasitic
25.3%Antimalarial25.3%Atovaquone-Proguanil Hcl100%Part D≥19 patientsMusculoskeletal
13.9%Nonsteroidal Anti-inflammatory Drug13.9%Naproxen100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 2012–2023 per NIH RePORTER. The latest:
- Evaluation of novel tuberculosis LAM assays among people living with HIV and sepsis
University of Virginia
FY2023$187,055R21AI172637 - Evaluation of novel tuberculosis LAM assays among people living with HIV and sepsis
University of Virginia
FY2022$247,160R21AI172637 - Effects of TB and TB treatment on the pediatric intestinal microbiome
University of Virginia
FY2021$243,250R21AI154259
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Fluoroquinolones and rifampin combination in the backdrop of heteroresistant tuberculosis
Antimicrobial Agents and Chemotherapy
2025 - Clinical standards for the management of adverse effects during treatment for TB
The International Journal of Tuberculosis and Lung Disease
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Mark Deboer, MD
University of Virginia
Jaideep Kapur, MD
University of Virginia
Mark Quigg, MD, MSc
University of Virginia
Ryan Gentzler, MD
University of Virginia
Thomas Walsh, MD
Cornell University
Douglas Richman, MD
University of California San Diego
Vance Fowler, MD
Duke University
Myron Cohen, MD
University of North Carolina at Chapel Hill School of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”